Literature DB >> 11751768

Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.

Ralf René Reinert1, Adnan Al-Lahham, Maria Lemperle, Christoph Tenholte, Claudia Briefs, Stefan Haupts, Hans Hubert Gerards, Rudolf Lütticken.   

Abstract

Continuous nationwide surveillance of antibiotic resistance in invasive pneumococcal disease was performed in Germany between 1992 and 2000, with a total of 2586 strains being isolated. The average resistance rates to erythromycin and clindamycin were 7.7% and 3.5%, respectively, throughout the study period; 3.3% of strains were found to have intermediate resistance to penicillin. Over the study period an increase in both macrolide and penicillin resistance was observed. The percentage of strains exhibiting reduced susceptibility to penicillin increased from 1.8% in 1992 to 5.8% in 2000. A dramatic increase in resistance was observed with erythromycin, where the resistance rate rose from 3.0% in 1992 to 15.3% in 2000. Of the erythromycin-resistant strains, 86 (43.4%) and 111 (56.1%) belonged to the erm(B) and mef types of resistance, respectively. An analysis of macrolide consumption data during the study period showed that erythromycin resistance was highly correlated to the consumption of newer bd and od macrolides (r = 0.89, P < 0.01).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751768     DOI: 10.1093/jac/49.1.61

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Molecular epidemiology of pneumococcal carriage among children with upper respiratory tract infections in Hanoi, Vietnam.

Authors:  D Bogaert; N T Ha; M Sluijter; N Lemmens; R De Groot; P W M Hermans
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates.

Authors:  Angela B Brueggemann; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.

Authors:  Maria Pia Montanari; Marina Mingoia; Ileana Cochetti; Pietro Emanuele Varaldo
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

5.  Genetic basis of erythromycin resistance in oral bacteria.

Authors:  A Villedieu; M L Diaz-Torres; A P Roberts; N Hunt; R McNab; D A Spratt; M Wilson; P Mullany
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

6.  Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae.

Authors:  Miika Bergman; Solja Huikko; Pentti Huovinen; Pirkko Paakkari; Helena Seppälä
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

7.  Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.

Authors:  Ralf René Reinert; Adrian Ringelstein; Mark van der Linden; Murat Yücel Cil; Adnan Al-Lahham; Franz-Josef Schmitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992-2008).

Authors:  Matthias Imöhl; Ralf René Reinert; Mark van der Linden
Journal:  Int J Microbiol       Date:  2010-06-30

9.  Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.

Authors:  C García-Rey; L Aguilar; F Baquero; J Casal; J E Martín
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

Review 10.  Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective.

Authors:  Stephan Harbarth; Werner Albrich; Christian Brun-Buisson
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.